Skip to Content
Søk Menu

Nordic AML Insights: Research and Ph.D. Contributions

/ Jan Andreasen
AML

AML Insights: What’s New in the Field

/ Jan Andreasen
AML
Michael Savona

AML: Oral Decitabine–Cedazuridine Is Equivalent to Intravenous Decitabine

/ Michael Savona
AMLLeukemi Play the Video

Liposomal Daunorubicin + Cytarabine: Enhanced Synergistic Antineoplastic Effect in AML Treatment

/ Andrea Lenartova / Jan Andreasen
AML
Gunnar Juliusson

Swedish Result for Cytarabine Treatment of Secondary AML is Better than the Register Studies

/ Gunnar Juliusson
AML Play the Video
Hanna Duàn

Genomic Subtypes of AML Determines Sensitivity to NK Cell Cytotoxicity

/ Hanna Duàn
AMLASH24 Play the Video
Gunnar Juliusson

Cytarabine Dose Intensification Improves Survival in Older Patients with AML

/ Gunnar Juliusson
AML Play the Video

The Development of New Treatment Options within AML Is Slower Than in Other Disease Areas within Hematology

/ BestPractice Nordic
AMLEHA24
Nikolaj Nitschke

Functional Characterization for Germline Variants in Patients with MDS and AML

/ Nikolaj Juul Nitschke
AMLEHA24 Play the Video

Drug Sensitivity Screening to Guide Clinical Decisions for Hematologic Cancers

/ Sigrid S. Skånland
AMLCLL
Jad Othman

MRD Status in NPM1 Mutated AML Should Be a Part of the Selection of Patients for Transplant in First Remission

/ Jad Othman
AMLASH23 Play the Video

ASH 2023: Oral Decitabine-Cedazuridine Tablet Shows Promise for AML Treatment in Phase III Study

/ BestPractice Nordic
AMLASH23
Hent flere
Back to top